WOAH Reference Laboratory Reports Activities 2023

Activities in 2023

This report has been submitted : 6 juin 2024 12:54

Laboratory Information

Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Infectious bursal disease (Gumboro disease)
Address of laboratory:	Anses, Laboratoire de Ploufragan-Plouzané-Niort, BP53, 41 rue de Beaucemaine, 22440 Ploufragan, FRANCE
Tel.:	+33 2 96 01 62 22
E-mail address:	nicolas.eterradossi@anses.fr
Website:	https://www.anses.fr/fr/content/laboratoire-de-ploufragan-plouzan%C3%A9-niort
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Nicolas Eterradossi
Name (including Title and Position) of WOAH Reference Expert:	Dr Nicolas Eterradossi, Head of laboratory
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
AGID		1142	0
Virus neutralisation (VN)		464	0
Direct diagnostic tests		Nationally	Internationally
viral isolation or titration on chicken embryo fibroblasts		22	0
Partial amplification of IBDV genome (RT-PCR for VP2 or VP1 genes)		1062	0
Detection of IBDV genome by real-time RT-PCR (rRT-PCR)		734	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

				AMOUNT SUPPLIED		

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAH MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Monospecific antisera	ELISA - AGID	Produced and provided	8 ml	0 ml	1	FRANCE,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAH Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

Yes

NAME OF THE NEW TEST OR DIAGNOSTIC METHOD DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
New pathotyping method based on early changes in blood parameters	Molinet et al., 2023, doi: 10.1186/s13567-023-01222-5

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

No

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Genetic immunity against IBDV	3 years	To characterize the viral and cellularfactors involved in the establishment of IBDV persistent infections, both in vitro and in vivo	National Center for Biotechnology (CNB)	SPAIN
Collaborations on IBDV	ongoing	Collaboration to characterize virus strains and virus-host interactions	The pirbright Institute	UNITED KINGDOM

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAH?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

The laboratory took advantage of the collection of fecal samples from wild birds in France for 1 year during a project on another pathogen to look for the presence of IBDV traces. No IBDV could be detected in the samples from those wild birds (results to be published within report of a wider study).

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1
Molinet A., Courtillon C., Bougeard S., Keita A., Grasland B., Eterradossi N. and Soubies S. 2023. "Infectious bursal disease virus: predicting viral pathotype using machine learning models focused on early changes in total blood cell counts." Veterinary Research 54 (1): 101. https://doi.org/10.1186/s13567-023-01222-5.

b) International conferences:

c) National conferences:

1
Courtillon, C. Prédiction du pathotype du virus de la bursite infectieuse à l'aide de modèles se basant sur les changements précoces de la numération des cellules sanguines totales. Journée Avicole et Cunicole d'Information et d'Echange de l'Anses, Ploufragan, 16 novembre 2023.

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	compliance certificate ISO 17025 2023-2024.pdf	Compliance certificate ISO 17025 2023-2024.pdf

19. Is your quality management system accredited?

No

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory quality management system and procedures comply with nationally applicable regulations and cover biorisk (biosafety and biosecurity) evaluation and management, in line with recommandations of chapter 1.1.4 of OIE Manual

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOAH Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOAH REFERENCE LABORATORIES
Revision of IBD chapter of OIE manual	ongoing revision	Anses Ploufragan-Plouzané-Niort, France Harbin Veterinary Research Institute, PR China

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen?

No

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAH?

No

29. Additional comments regarding your report:

Yes

Human resources issues in WOAH IBD reference laboratory (two senior scientists missing in 2023) interfered with IBD research and reference activities. new organization defined, recruitments in progress and new projects launched for 2024